Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

ClinicalTrials.gov ID: NCT02844439

Public ClinicalTrials.gov record NCT02844439. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

Study identification

NCT ID
NCT02844439
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Kadmon Corporation, LLC
Industry
Enrollment
40 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2016
Primary completion
Apr 29, 2020
Completion
Apr 29, 2020
Last update posted
Sep 21, 2021

2016 – 2020

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Center for Neurosciences Tucson Arizona 85718
City of Hope Duarte California 91010
University of California, San Francisco (UCSF) San Francisco California 94143
University of Colorado Cancer Center Aurora Colorado 80045
Massachusetts General Hospital Boston Massachusetts 02114
Dana Farber Cancer Institute Boston Massachusetts 02215
Henry Ford Hospital Detroit Michigan 48202
Columbia University, Herbert Irving Comprehensive Cancer Center New York New York 10032
Cleveland Clinic Cleveland Ohio 44195
UT MD Anderson Cancer Center Houston Texas 77030
Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Glioblastoma trials

Other public records listing Glioblastoma. Sorted by last update posted; newest first. Not a recommendation.

All Glioblastoma trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02844439, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 21, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02844439 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →